Could gonadotropin-releasing hormone analogs be helpful in the treatment of triple-negative breast cancer?
Silvia Paola Corona(Hôpital Cardiologique du Haut-Lévêque), Daniele Generali(University of Trieste), Giovanni Allevi(Istituti Ospitalieri di Cremona), Sergio Aguggini(Istituti Ospitalieri di Cremona), Daniele Zanoni(Istituti Ospitalieri di Cremona), Carla Strina(Istituti Ospitalieri di Cremona), Manuela Milani(Humanitas University), Giandomenico Roviello(University of Florence)
Cited by 6
Related Papers
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
|Journal of Clinical Oncology|2012|368
The Role of ATF4 Stabilization and Autophagy in Resistance of Breast Cancer Cells Treated with Bortezomib
|Cancer Research|2009|298
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
|JNCI Journal of the National Cancer Institute|2018|282
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268